PRESS RELEASE

Sosei Heptares Confirms Board and Executive Management Appointments at 31st Annual Shareholders' Meeting

- *Mr. Chris Cargill, currently Chief Financial Officer, appointed to the additional and new role of Group Chief Operating Officer*

Tokyo, Japan and Cambridge, UK, 24 March 2021 – Sosei Group Corporation ("the Company"; TSE: 4565) today confirms its Board and Executive Management appointments in accordance with requirements under the Companies Act. Board appointments were approved at the Company's 31st Shareholders' Meeting today and are effective from 24 March 2021. Executive Management appointments were approved at the Company's Board of Directors meeting today, following earlier announcement at the 31st Shareholders' Meeting, and are effective from 1 April 2021. Mr. Chris Cargill, currently the Group's Chief Financial Officer, has been appointed to the additional and new role of Group Chief Operating Officer, reporting to President and Chief Executive Officer, Mr. Shinichi Tamura.

Details of the appointments are as follows:

Board of Directors (effective 24 March 2021)

Chairman of the Board	Shinichi Tamura (reappointed)
Independent External Director	Tomohiro Tohyama (reappointed)
Independent External Director	Kuniaki Kaga (reappointed)
Independent External Director	David Roblin (reappointed)
Independent External Director	Noriaki Nagai (reappointed)
Independent External Director	Rolf Soderstrom (reappointed)

Executive Officers (effective 1 April 2021)

Representative Executive Officer, Chairman, President and Chief Executive Officer	Shinichi Tamura
Executive Vice Chairman	Malcolm Weir
Group Chief Operating Officer and Chief Financial Officer	Chris Cargill
EVP, Chief Medical Officer	Tim Tasker
EVP, Group Chief Compliance Officer	Kazuhiko Yoshizumi
EVP, Representative Director President, Sosei Co. Ltd.	Tadayoshi Yasui

Chairman, President and CEO, Shinichi Tamura, said: "I would like to congratulate Chris on his expanded role. He has made crucial contributions broadly across the business as we have evolved and executed the Company's growth strategy over recent years. I am confident that with the current leadership team, Sosei Heptares is well placed to deliver on its goals and generate value for its shareholders."

PRESS RELEASE

Commenting at the 31st Shareholder Meeting, Mr Tamura added: "Sosei Heptares made great progress in 2020 and we are delighted to see this continuing into 2021. This progress has allowed us to successfully execute our strategy focused on leveraging our world-class platform, discovery, and early development capabilities to advance and extend a portfolio of partnered programs. During the past 12 months, we have added several major partnering agreements around our early-stage programs and reinforced our position as a drug discovery and development partner of choice. We also entered several strategic technology collaborations with innovative companies designed to strengthen our platform and enhance our discovery and future partnering opportunities, extending this beyond GPCRs for the first time. In addition, we completed a successful capital raising to support the rapid advancement of our extensive pipeline and our ambitious strategic growth plans, which could include a potentially transformative acquisition. With our clear strategy, our talented team, and a strong financial position, we can look forward to 2021 with great optimism."

-ENDS-

About Sosei Heptares

We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases.

We have established partnerships with some of the world's leading pharmaceutical companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Novartis, Pfizer and Takeda and additionally with multiple emerging technology companies. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.

"Sosei Heptares" is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.

For more information, please visit https://www.soseiheptares.com/
LinkedIn: @soseiheptaresco | Twitter: @soseiheptaresco | YouTube: @soseiheptaresco

PRESS RELEASE

Enquiries:

Sosei Heptares – Media and Investor Relations
Hironoshin Nomura, SVP Investor Relations and Corporate Strategy
+81 (0)3 6679 2178 | Hironoshin.Nomura@SoseiHeptares.com

Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures
+81 (0)3 5210 3399 | IR@SoseiHeptares.com

Citigate Dewe Rogerson (for Sosei Heptares)
Yas Fukuda – Japanese Media
+81 (0)3 4360 9234 | Yas.Fukuda@citigatedewerogerson.com

Mark Swallow, David Dible – International Media
+44 (0)20 7638 9571 | SoseiHeptares@citigatedewerogerson.com

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products. Various risks may cause Sosei Group Corporation's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.